GlassScriptPhysician profile
Nicholas M Fenwick
NPI 1154082808
$2,566.07
in general payments reported to CMS, 2019-2025
35 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $184 · 2023: $399 · 2024: $850 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320 · Education: $62.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.86 |
| Education | $62.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $328.29 | 2024-2025 | Ozempic, Tresiba, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $250.71 | 2022-2024 | Farxiga |
| Radius Health, INC. | $238.20 | 2023-2025 | Tymlos |
| Corcept Therapeutics | $158.63 | 2025 | Korlym |
| Amgen INC. | $145.75 | 2024-2025 | Evenity, Prolia, Repatha |
| Horizon Therapeutics Plc | $132.66 | 2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $117.21 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $106.41 | 2023 | Oxlumo |
| Novartis Pharmaceuticals Corporation | $101.44 | 2024 | |
| Abbvie INC. | $78.80 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $74.02 | 2025 | Isturisa |
| Lilly USA, LLC | $72.36 | 2025 | Jardiance |
| Kyowa Kirin, INC. | $64.87 | 2025 | |
| Mallinckrodt Hospital Products INC. | $61.47 | 2024-2025 | Acthar, Terlivaz |
| Organon LLC | $52.55 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.42 | 2024-2025 | Jardiance |
| Madrigal Pharmaceuticals | $45.86 | 2025 | Rezdiffra |
| Xeris Pharmaceuticals, INC. | $43.40 | 2024 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $43.14 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Vantive US Healthcare LLC | $39.43 | 2025 | Renal - Pd |
| Sanofi-Aventis U.S. LLC | $34.25 | 2024 | |
| Neurocrine Biosciences, INC. | $33.48 | 2025 | |
| Mannkind Corporation | $32.32 | 2023-2024 | Afrezza |
| Medtronic, INC. | $29.99 | 2023 | Minimed 780g |
| Calliditas Therapeutics US INC. | $29.86 | 2024-2025 | Tarpeyo |
| Dexcom, INC. | $29.33 | 2024 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $29.21 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sandoz INC. | $27.23 | 2025 | Hyrimoz |
| Insulet Corporation | $24.15 | 2024 | Omnipod |
| Ultragenyx Pharmaceutical INC. | $19.08 | 2024 | Crysvita |
| Acella Pharmaceuticals, LLC | $16.37 | 2025 | NP Thyroid 60 |
| Amphastar Pharmaceuticals, INC. | $15.53 | 2024 | |
| Chiesi USA, INC. | $14.43 | 2024 | Mycapssa |
| Amneal Pharmaceuticals LLC | $13.64 | 2025 | Unithroid |
| Apellis Pharmaceuticals, INC. | $13.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Fenwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.